Equities analysts forecast that BioTelemetry Inc (NASDAQ:BEAT) will announce sales of $111.08 million for the current fiscal quarter, according to Zacks Investment Research. Two analysts have issued estimates for BioTelemetry’s earnings, with the highest sales estimate coming in at $111.10 million and the lowest estimate coming in at $111.06 million. BioTelemetry reported sales of $101.36 million during the same quarter last year, which indicates a positive year-over-year growth rate of 9.6%. The firm is scheduled to announce its next quarterly earnings report on Wednesday, July 24th.
According to Zacks, analysts expect that BioTelemetry will report full-year sales of $446.22 million for the current fiscal year, with estimates ranging from $445.03 million to $447.40 million. For the next financial year, analysts expect that the company will post sales of $494.29 million, with estimates ranging from $490.37 million to $498.20 million. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side analysts that follow BioTelemetry.
BioTelemetry (NASDAQ:BEAT) last posted its earnings results on Thursday, April 25th. The medical research company reported $0.42 EPS for the quarter, meeting the consensus estimate of $0.42. The firm had revenue of $103.98 million for the quarter, compared to analyst estimates of $104.17 million. BioTelemetry had a return on equity of 23.36% and a net margin of 11.86%. BioTelemetry’s revenue for the quarter was up 10.0% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.39 earnings per share.
Several equities analysts recently commented on BEAT shares. BidaskClub lowered Zynerba Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday, June 26th. ValuEngine downgraded shares of United Rentals from a “sell” rating to a “strong sell” rating in a research note on Thursday. Benchmark set a $82.00 price objective on shares of BioTelemetry and gave the company a “buy” rating in a research note on Tuesday, April 2nd. Dougherty & Co restated a “buy” rating and issued a $140.00 price objective (up previously from $115.00) on shares of Proofpoint in a research note on Friday, April 26th. Finally, Zacks Investment Research downgraded shares of Hancock Jaffe Laboratories from a “buy” rating to a “hold” rating in a research note on Wednesday, June 26th. Two investment analysts have rated the stock with a sell rating, one has issued a hold rating and six have assigned a buy rating to the stock. The stock has an average rating of “Hold” and an average price target of $79.57.
NASDAQ:BEAT traded down $1.29 during trading hours on Friday, hitting $45.27. The company’s stock had a trading volume of 748,002 shares, compared to its average volume of 313,770. The company has a market capitalization of $1.53 billion, a PE ratio of 23.34 and a beta of 1.33. The company has a fifty day simple moving average of $48.75. The company has a debt-to-equity ratio of 0.57, a current ratio of 1.99 and a quick ratio of 1.84. BioTelemetry has a 52-week low of $44.57 and a 52-week high of $80.92.
In other BioTelemetry news, Director Kirk E. Gorman sold 5,518 shares of BioTelemetry stock in a transaction on Tuesday, April 30th. The shares were sold at an average price of $54.37, for a total value of $300,013.66. Following the transaction, the director now owns 178,833 shares in the company, valued at approximately $9,723,150.21. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 6.50% of the stock is owned by company insiders.
Several institutional investors and hedge funds have recently made changes to their positions in BEAT. Eagle Asset Management Inc. acquired a new position in shares of BioTelemetry in the 1st quarter valued at $31,052,000. Carillon Tower Advisers Inc. boosted its holdings in shares of BioTelemetry by 284.2% in the 1st quarter. Carillon Tower Advisers Inc. now owns 478,632 shares of the medical research company’s stock valued at $29,972,000 after purchasing an additional 354,043 shares during the last quarter. Rothschild & Co. Asset Management US Inc. boosted its holdings in shares of BioTelemetry by 712.0% in the 1st quarter. Rothschild & Co. Asset Management US Inc. now owns 310,504 shares of the medical research company’s stock valued at $19,444,000 after purchasing an additional 272,265 shares during the last quarter. Deutsche Bank AG boosted its holdings in shares of BioTelemetry by 119.7% in the 4th quarter. Deutsche Bank AG now owns 310,751 shares of the medical research company’s stock valued at $18,556,000 after purchasing an additional 169,306 shares during the last quarter. Finally, Meritage Portfolio Management acquired a new position in shares of BioTelemetry in the 1st quarter valued at $9,848,000. Institutional investors own 90.76% of the company’s stock.
BioTelemetry, Inc, a remote medical technology company, provides remote cardiac monitoring, remote blood glucose monitoring, centralized core lab services for clinical trials, and original equipment manufacturing services for healthcare and clinical research customers worldwide. It operates in Healthcare, Research, and Corporate and Other segments.
Featured Story: Purposes and Functions of the Federal Reserve
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for BioTelemetry Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioTelemetry and related companies with MarketBeat.com's FREE daily email newsletter.